Methylin Shortage: What Providers and Prescribers Need to Know in 2026

The methylphenidate shortage that began in 2023 continues to create significant challenges for prescribers managing ADHD patients. As patients contact your office unable to fill their prescriptions, having a clear clinical framework for managing the shortage is essential. This guide summarizes the current landscape and offers practical strategies for 2026.

Current Shortage Status

Methylphenidate has been on the FDA Drug Shortage list since July 26, 2023. As of June 2026, the shortage remains active but has improved from its 2023-2024 peak. Multiple manufacturers — Alvogen, Aurobindo, Epic Pharma, Granules Pharmaceuticals, Lannett, Oryza Pharmaceuticals, Sandoz, SpecGx, and Teva — have reported limited or no availability for specific dose strengths at various points. Generic extended-release formulations (18 mg, 27 mg, 36 mg, 54 mg) have been the most consistently affected.

The DEA raised the methylphenidate production quota by approximately 9% in October 2025, following a 25% increase in d-amphetamine quotas — the first increase since 2021. Supply is improving incrementally, but experts do not anticipate a definitive end to shortage conditions in 2026.

Clinical Implications of the Shortage

Patients who miss doses or go without medication face real clinical consequences. ADHD symptom recurrence affects executive function, academic and occupational performance, relationships, and safety (e.g., driving). For adult patients, untreated ADHD may contribute to anxiety, depression, and increased risk-taking behavior. Discontinuation should be managed carefully — particularly for patients on higher doses where abrupt stoppage may cause rebound symptoms.

Prescribing Strategies for the Shortage

1. Write Prescriptions with Flexibility

Where clinically appropriate, write prescriptions in a way that gives pharmacists and patients options:

Consider writing for the dose closest to what the patient needs, noting that the pharmacist may dispense a different manufacturer's generic

For ER formulations, consider whether an IR regimen could achieve similar coverage if ER is unavailable (e.g., twice or three times daily IR dosing)

Consider writing a second prescription for an alternative formulation or medication that can be filled if the first is unavailable (per your state's Schedule II prescription rules)

2. Consider Switching Within the Methylphenidate Class

If a patient's usual formulation is consistently unavailable, switching to another methylphenidate product may be clinically appropriate before moving to a different drug class. Options include:

Jornay PM (methylphenidate ER capsule taken in the evening): Uses a unique delayed-release mechanism; may be available when other ER formulations are not

Relexxii (methylphenidate ER tablet): Osmotic delivery system alternative to Concerta; available in 18, 27, 36, 54, and 72 mg

Daytrana (methylphenidate transdermal patch): A patch-based delivery system; availability may differ from oral formulations

3. Switching to Amphetamine-Based Stimulants

For patients who cannot consistently find methylphenidate, amphetamine-based stimulants are the most pharmacologically similar alternative. Key options in 2026:

Vyvanse (lisdexamfetamine): Brand-name generally well-stocked; generic lisdexamfetamine improving in availability. Long duration (10-14 hrs), lower abuse potential due to prodrug mechanism.

Adderall XR (amphetamine/dextroamphetamine ER): Also in shortage but availability varies by location; some areas have better supply than others.

Azstarys (serdexmethylphenidate/dexmethylphenidate): A newer Schedule II option; serdexmethylphenidate is a prodrug of d-methylphenidate. May be available when traditional methylphenidate products are not.

4. Non-Stimulant Alternatives

For patients who cannot find stimulant medications or who have contraindications to stimulants, non-stimulant ADHD medications are unaffected by DEA quotas and widely available:

Atomoxetine (Strattera): SNRI approved for ADHD; generic available and affordable. Onset 4-6 weeks. Useful for patients with anxiety, tic disorders, or substance use concerns.

Viloxazine (Qelbree): Non-stimulant SNRI approved for ADHD in ages 6+ and adults; daily dosing; not a controlled substance.

Guanfacine ER (Intuniv): Alpha-2 agonist FDA-approved for ADHD; effective for hyperactivity and impulsivity; can be used as monotherapy or adjunct.

Clonidine ER (Kapvay): Alpha-2 agonist; useful for patients with comorbid sleep problems or tic disorders.

Telehealth and Prescribing Rules in 2026

The DEA extended COVID-era telehealth flexibilities through at least December 31, 2026. Providers may continue to prescribe Schedule II controlled substances, including methylphenidate, via telehealth without requiring an in-person evaluation first. This makes it easier for patients to reach prescribers during the shortage — including to discuss alternative medications.

How to Help Your Patients Find Their Medication

When patients call your office unable to fill their prescription, directing them to medfinder for providers can help them locate in-stock pharmacies without burdening your staff. medfinder contacts pharmacies on the patient's behalf and texts them results — saving time for both patients and your team.

For more strategies on supporting your patients through the shortage, see: How to Help Your Patients Find Methylin in Stock: A Provider's Guide.